Discovery of β‐Dihydroagarofuran‐Type Sesquiterpenoids from the Leaves of Tripterygium wilfordii with Neuroprotective Activities

Shuhui Dong,Bin Lin,Xiaobian Xue,Ming Bai,Xiaoxiao Huang,Shaojiang Song
DOI: https://doi.org/10.1002/cjoc.202000471
IF: 5.56
2021-01-13
Chinese Journal of Chemistry
Abstract:<p>Nine undescribed dihydro‐β‐agarofuran sesquiterpenoid derivatives (<b>1</b>–<b>9</b>), along with a known analogue (<b>10</b>) were obtained from the leaves of Tripterygium wilfordii. Their gross structures were determined via extensive spectroscopic data, and the absolute configurations were elucidated by means of single‐crystal X‐ray diffraction analysis and electron circular dichroism (ECD) techniques which include ECD exciton chirality, octant rule of saturated cyclohexanone and comparison between the experimental and calculated ECD spectra. All the isolated compounds were tested for their neuroprotective activities against H<sub>2</sub>O<sub>2</sub>‐induced cell injury in human neuroblastoma SH‐SY5Y cells. Compounds <b>5</b> and <b>6</b> improved cell viability by 16.15 and 15.12% compared with the H<sub>2</sub>O<sub>2</sub> treated group at 25 μM, respectively.</p><p>This article is protected by copyright. All rights reserved.</p>
chemistry, multidisciplinary
What problem does this paper attempt to address?
This paper aims to discover β - dihydroagarofuran - type sesquiterpenoids with neuroprotective activity from the leaves of Tripterygium wilfordii. Specifically, the researchers isolated nine undescribed β - dihydroagarofuran - type sesquiterpenoid derivatives (1 - 9) and one known analogue (10) from the leaves of Tripterygium wilfordii, and determined the structures and absolute configurations of these compounds by various spectroscopic methods. In addition, the study also tested the neuroprotective effects of these compounds against H₂O₂ - induced cell damage in human neuroblastoma SH - SY5Y cells. ### Research Background and Innovation Points - **Background**: Tripterygium wilfordii has a long history of use in traditional Chinese medicine, and in recent years, more and more research has been carried out on its bioactive components. Although hundreds of compounds have been identified from its roots and are widely used in clinical treatment of diseases such as rheumatoid arthritis, relatively little research has been done on the leaf part. Therefore, this study aims to promote the sustainable use of Tripterygium wilfordii. - **Innovation Points**: For the first time, β - dihydroagarofuran - type sesquiterpenoids with neuroprotective activity were isolated from the leaves of Tripterygium wilfordii. These compounds have a highly oxidized tricyclic skeleton and multiple consecutive stereocenters, and contain multiple ester groups, increasing the structural diversity of natural β - dihydroagarofuran - type sesquiterpenoids. ### Main Observations and Conclusions - **Structure Identification**: The structures and absolute configurations of nine new compounds and one known compound were determined by high - resolution mass spectrometry (HRESIMS), nuclear magnetic resonance (NMR) analysis, single - crystal X - ray diffraction analysis, and electronic circular dichroism (ECD) techniques. - **Neuroprotective Activity**: All the isolated compounds were tested for neuroprotective activity in SH - SY5Y cells. Among them, compounds 5 and 6 showed significant neuroprotective effects at a concentration of 25 μM, increasing cell viability by 16.15% and 15.12% respectively, which was better than the positive control Trolox (increasing cell viability by 7.87% at the same concentration). ### Conclusion In summary, the researchers successfully isolated and identified nine new β - dihydroagarofuran - type sesquiterpenoids and one known compound from the leaves of Tripterygium wilfordii. These compounds not only have complex structural features, but also show good neuroprotective activity in vitro experiments, especially compounds 5 and 6, which show significant cell - protecting effects. This finding provides important lead compounds for the development of new neuroprotective drugs.